10-Q: iTeos Therapeutics to Wind Down, Merge with Concentra

iTeos Therapeutics reports significant losses and plans to wind down operations, entering a merger agreement with Concentra Biosciences for $10.047 cash plus a contingent value right per share.

Summary

• iTeos Therapeutics reported a net loss of $113.3 million for the six months ended June 30, 2025, a significant increase from $45.3 million in the same period of 2024.
• The company's lead clinical-stage program, belrestotug, was terminated following disappointing interim analysis results from GALAXIES Lung-201 and GALAXIES H&N-202 trials.
• The collaboration agreement with GlaxoSmithKline (GSK) for belrestotug was terminated by GSK on May 13, 2025, leading to a $32.0 million settlement payment from iTeos to GSK.
• iTeos announced its intention to wind down clinical and operational activities on May 28, 2025, expecting completion by the third quarter of 2025.
• A merger agreement was signed on July 18, 2025, with Concentra Biosciences, LLC, for an acquisition price of $10.047 in cash plus one Contingent Value Right (CVR) per share.
• The CVR entitles holders to contingent payments based on Closing Net Cash exceeding $475 million and 80% of net proceeds from the disposition of certain CVR Products (EOS-984, EOS-215, preclinical obesity, PTPNI1/2 programs) within six months post-merger.
• Restructuring costs of $16.3 million were recorded for severance in the three months ended June 30, 2025, with an additional $8.2 million expected in July 2025.
• The company initiated employee terminations in Belgium (mid-August 2025) and the U.S. (July 7, 2025).
• Lease agreements in Belgium were terminated in July 2025, incurring an expected cost of $2.4 million for remaining obligations.
• The company's Employee Stock Purchase Plan (ESPP) was terminated on July 18, 2025, with participant refunds planned.
• A significant portion of the $7.0 million repayable grant liability to the Walloon Region was relieved in July 2025, with only $0.2 million (current portion) and $1.5 million (advance payments) remaining payable.

Sentiment

Score: 2

Explanation: The sentiment is overwhelmingly negative due to the termination of the lead drug program, the end of a major collaboration, the decision to wind down operations, and the explicit mention of 'substantial doubt about the company's ability to continue as a going concern.' While a merger agreement offers a path for shareholders, it is a consequence of significant operational failures and implies the end of the company as an independent, operating entity. The CVR offers speculative future value, but the immediate outlook is dire for the company's original mission.

Positives

• The company has a substantial cash and investments balance of $590.0 million as of June 30, 2025, providing liquidity for the wind-down and merger process.
• The merger agreement with Concentra Biosciences provides a clear path for shareholder value realization, including a cash component and potential upside via CVRs from remaining assets.
• The substantial relief of the $7.0 million repayable grant liability from the Walloon Region reduces future financial obligations by approximately $5.3 million.

Negatives

• The net loss significantly increased to $113.3 million for the six months ended June 30, 2025, compared to $45.3 million in the prior year, primarily due to the absence of collaboration revenue and increased R&D expenses related to program termination.
• The termination of the belrestotug development program and the GSK collaboration represents a major setback, as it was the company's lead clinical-stage product candidate.
• The company has announced its intention to wind down clinical and operational activities, indicating a cessation of its core business operations.
• There is substantial doubt about the company's ability to continue as a going concern if the merger is not consummated or an alternative strategic transaction is not realized.
• The company incurred $16.3 million in restructuring costs for severance in Q2 2025, with an additional $8.2 million expected, reflecting significant employee terminations.
• Lease termination costs of $2.4 million are expected due to the wind-down of operations in Belgium and the U.S.

Risks

• The pending acquisition by Concentra may not be completed within the anticipated timeframe or at all, which could adversely affect the business, financial results, and operations.
• Failure to complete the merger could lead to a decline in common stock price, negative publicity, and strained relationships with stakeholders.
• The company may be required to pay Concentra an $8.4 million termination fee under certain circumstances if the merger agreement is terminated.
• If Concentra terminates the merger due to Closing Net Cash being less than $475.0 million, the company may be required to reimburse Concentra up to $0.5 million in expenses.
• The pendency of the transaction could cause substantial disruptions and uncertainty in the company's wind-down process, diverting management and employee attention.
• Securities class action and derivative lawsuits related to the transaction could result in substantial costs and potentially delay or prevent the merger.
• Stockholders will not participate in any financial upside to the business after the merger other than through the CVRs, and there is no assurance that any CVR consideration will be received.
• The U.S. federal income tax treatment of the CVRs is unclear, potentially leading to adverse tax consequences for holders.
• The company's ability to fund operations through 2027 is based on assumptions that may prove incorrect, and available capital resources could be used sooner than expected if the merger is not completed or an alternative strategic transaction is not found, potentially leading to dissolution and liquidation.

Future Outlook

The company expects to substantially complete the wind-down of its clinical and operational activities in the third quarter of 2025. The proposed merger with Concentra Biosciences is anticipated to close in the third quarter of 2025, subject to customary closing conditions including a majority tender of shares and a minimum Closing Net Cash of $475 million. If the merger is not consummated or an alternative strategic transaction is not realized, the company expects to incur additional losses and its Board of Directors may decide to pursue a dissolution and liquidation. The company believes its existing cash and investments can fund operating expenses and capital expenditure requirements through 2027, but this is contingent on the successful execution of the merger or an alternative strategic transaction.

Management Comments

• "We are currently in the process of winding down our clinical activities and expect to complete the wind down in the third quarter of 2025."
• "In the event that the Merger is not consummated and we are unable to realize a strategic alternative and until such time as we are fully wound down, we expect to incur additional losses."
• "Failure to manage discretionary spending or execute on a strategic alternative, including the Merger, will adversely impact our ability to achieve our intended business objectives."
• "If we do not successfully consummate the Merger or other strategic transaction, the Board of Directors may decide to pursue a dissolution and liquidation of the Company."
• "We believe our existing cash and cash equivalents and available-for-sale securities will enable us to fund our operating expenses and capital expenditure requirements through 2027."

Industry Context

This filing reflects a significant shift in the immuno-oncology sector, where clinical trial failures are common and can lead to rapid strategic pivots. The termination of a lead program (belrestotug) and subsequent wind-down and acquisition by another entity (Concentra Biosciences) highlights the high-risk, high-reward nature of drug development. The CVR structure in the merger agreement is a common mechanism in biotech acquisitions to provide shareholders with potential future value from pipeline assets that are not yet fully de-risked, reflecting the inherent uncertainty in early-stage drug programs.

Comparison to Industry Standards

• The termination of a Phase 3 registrational study (GALAXIES Lung-301) and Phase 2 trials (GALAXIES Lung-201, GALAXIES H&N-202) for belrestotug due to insufficient efficacy (not meeting PFS endpoint, trend below ORR threshold) is a common occurrence in oncology drug development, where many candidates fail in late-stage trials despite promising early data. For example, similar setbacks have been seen with other TIGIT inhibitors from companies like Gilead Sciences (domvanalimab) and Merck (vibostolimab) in certain indications, underscoring the challenges in this pathway.
• The decision to wind down operations and pursue a merger following clinical failure is a standard strategic response for small to mid-cap biotech companies to maximize remaining shareholder value, rather than attempting to pivot to new, costly development programs without sufficient capital or a clear path forward. This contrasts with larger pharmaceutical companies that might absorb such failures and reallocate resources internally.
• The use of a Contingent Value Right (CVR) in the acquisition by Concentra Biosciences is a common practice in biotech M&A, particularly when the acquiring company is interested in specific pipeline assets (EOS-984, EOS-215, preclinical obesity, PTPNI1/2 programs) but wants to share the risk and reward of their future development or disposition with the selling company's shareholders. This structure has been utilized in various biotech deals, such as the acquisition of Acceleron Pharma by Merck, where CVRs were tied to the success of specific drug candidates.

Related Party Transactions

• Boxer Capital, considered a related party due to its CEO serving on the Board of Directors at the time, purchased 1,142,857 shares of common stock for $20.0 million on May 10, 2024.
• RA Capital, historically a related party due to its partner on the Board and beneficial ownership exceeding 10%, purchased a pre-funded warrant for 5,714,285 shares for $100.0 million on May 10, 2024.
• RA Capital exchanged 900,000 shares of common stock for a pre-funded warrant on May 14, 2024, after which its beneficial ownership fell below the 10% threshold.
• RA Capital exercised its pre-funded warrants in full for 6,613,442 shares in cashless exercises during the six months ended June 30, 2025.

Stakeholder Impact

• **Shareholders**: Will receive $10.047 cash per share plus one CVR, which offers potential future contingent payments from the disposition of remaining pipeline assets. However, the value of the CVR is uncertain, and the company's original growth trajectory has ended.
• **Employees**: Significant impact due to planned and ongoing terminations in both Belgium and the U.S., with $16.3 million in severance costs already accrued and an additional $8.2 million expected.
• **Customers/Partners (GSK)**: The collaboration agreement has been terminated, with iTeos paying a $32.0 million settlement to GSK.
• **Creditors/Lenders**: The company's financial position is impacted by the wind-down and merger, but the substantial cash reserves and relief of grant liabilities mitigate immediate concerns. The going concern doubt highlights risk if the merger fails.
• **Suppliers/Vendors**: Contracts are generally cancelable on short notice, and the company is winding down clinical activities, likely reducing future engagements.

Next Steps

• Concentra Biosciences is expected to commence a tender offer by August 1, 2025, to acquire all outstanding shares.
• The merger is expected to close in the third quarter of 2025, subject to customary closing conditions.
• iTeos Belgium's first round of employee terminations is planned for mid-August 2025.
• The company expects to provide notice of termination for its Watertown, Massachusetts lease in the third quarter of 2025.
• iTeos Belgium and GSK are required to complete certain ongoing activities related to the wind-down and completion of clinical trials, including data migration and scientific publications.
• If the merger is not completed, the Board of Directors may decide to pursue a dissolution and liquidation of the company.

Key Dates

Recommendation

For existing shareholders, a 'hold' recommendation is appropriate given the pending acquisition by Concentra Biosciences. The offer includes a fixed cash component of $10.047 per share, providing a floor for the immediate value, plus a Contingent Value Right (CVR). While the CVR's value is speculative and dependent on future events (net cash exceeding $475 million and disposition of remaining pipeline assets), it offers potential upside beyond the cash component. Selling now would forgo this potential CVR value. For new investors, the stock is effectively an arbitrage play on the merger terms, and the company's operational future as an independent entity is ending, making a traditional 'buy' or 'sell' recommendation less applicable.

Keywords

Biotechnology, Immuno-oncology, Merger, Acquisition, Clinical Trials, Drug Development, TIGIT, ENT1, TREM2, Wind-down, SEC Filing, 10-Q, Contingent Value Right, CVR, Liquidation